I've seen it over and over again. Stock is downgraded by a number of firms.
Then after a month or two extraordinary news comes out and the sp doubles.
I get the feeling this might happen with INO.
Using the word negotiate obscures the truth about the way Medicare works. Medicare does not confer with medical providers about prices. Rather, it sets prices. If providers such as hospitals and pharmacies don't accept these prices, then they will not be reimbursed for treating Medicare patients. She is just playing on the strings of ignorants that is her base.
It's amazing. Here goes hillary clinton again, attacking the
big old bad pharmaceutical companies. She opens her
mouth and people still believe her. How stupid can people be.
The point also is that they developed personalized vaccines for three people. This is what confuses me/
"For decades, we've had cancer vaccines that fail to work, and we haven't really understood why," said Dr. Lynn Schuchter, a medical oncologist at the University of Pennsylvania and chair of the cancer research committee for the American Society of Clinical Oncology.
But recent advances in understanding and harnessing the immune system's power could be changing that, according to Schuchter, who was not involved in the new study.
"These are pretty dramatic results in the mouse model [of human cancers]," she said. "Studies like this are paving the way for effective vaccine approaches."
However, animal research does not always pan out in human trials.
The researchers, led by Dr. Ugur Sahin, of Johannes Gutenberg University in Mainz, Germany, used an approach that targets specific mutations in a given tumor.
The mutations unique to cancer cells are an "ideal" target for vaccines, according to Sahin's team. That's because the mutations are absent in healthy cells, and could stimulate the immune system to recognize tumors as foreign invaders and attack them.
However, since each person's cancer has a unique set of mutations, scientists are working toward customized vaccines -- tailored to target an individual patient's tumor.
Earlier this month, researchers reported initial results on just such a therapy. They developed personalized vaccines for three people with advanced melanoma, the deadliest form of skin cancer.
In each case, the vaccine triggered an increase in T-cells that could recognize the patient's cancer cells -- though the researchers stressed it's not yet clear whether the approach can actually beat back melanoma and extend people's lives.
The vaccines used in the current study are molecularly different from those in the melanoma trial, explained Dr. Alexandra Snyder Charen, an oncologist and immunotherapy researcher at Memorial Sloan Kettering Cancer Center, in New York City.
The latest approach could potentially "stimulate the whole immune system,
It would be administered to sick patients and as a vaccine. If you ask me I would say the first year would be in the billions.
Has anyone else noticed the after hour action their other biotech stocks. I own three that had a sharp move down and then later recovered nicely or broke even. Never seen heavy trading like this after hours on a Friday.